Table 2. . Bivariate and multivariate analyses for progression-free survival.
| Characteristics | Category | Univariate |
Multivariate | |
|---|---|---|---|---|
| p-value | HR (95% CI) | p-value | ||
| Age | ≥48 vs <48 years | 0.934 | – | – |
| Parity | Multiparous vs nulliparous | 0.061 | 1.89 (0.82–4.31) | 0.131 |
| Menopausal status | Postmenopause vs premenopause | 0.876 | – | – |
| BMI | ≥24.0 vs <24.0 kg/m2 | 0.619 | – | – |
| Serum CA-125 levels | ≥114.0 vs <114.0 U/ml | 0.094 | 1.42 (0.51–3.97) | 0.503 |
| Comorbidity | Yes vs No | 0.059 | 2.88 (1.20–6.89) | 0.018 |
| Upfront primary treatment | NACT and IDS vs PDS | 0.743 | – | – |
| Ascites | Yes vs No | 0.593 | – | – |
| FIGO stage | Advanced vs early | 0.130 | 1.35 (0.39–4.64) | 0.635 |
| Residual disease status | Optimal vs suboptimal | 0.313 | – | – |
| Histologic subtype | Type II vs Type I | 0.942 | – | – |
| Pretreatment SII | ≥610.2 vs <610.2 × 109 cells/l | 0.007 | 2.68 (1.17–6.09) | 0.020 |
BMI: Body mass index; CA: Cancer antigen; FIGO: International Federation of Gynecology and Obstetrics; HR: Hazard ratio; IDS: Interval debulking surgery; NACT: Neoadjuvant chemotherapy; PDS: Primary debulking surgery; Type I includes endometrioid carcinoma, clear cell carcinoma, mucinous carcinoma, and low-grade serous carcinomas; Type II includes high-grade serous carcinomas; SII: Systemic immune-inflammation index.